The effect of intravitreal bevacizumab (Avastin®) on ocular pulse amplitude in neovascular age-related macular degeneration
Ehud Rechtman1, Ingeborg Stalmans2, Joseph Glovinsky1, Christophe Breusegem2, Joseph Moisseiev1, Joachim Van Calster2, Alon Harris31Goldschleger Eye Institute, Sheba Medical Center, Ramat Gan, Israel; 2Department of Ophthalmology, University Hospitals Leuven, Leuven, Belgium; 3Department of Ophthalm...
Saved in:
Main Authors: | Ehud Rechtman, Ingeborg Stalmans, Joseph Glovinsky, et al |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2011
|
Subjects: | |
Online Access: | https://doaj.org/article/6639e7b2bd77417e9cb3d44df874ab2b |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Is monthly retreatment with intravitreal bevacizumab (Avastin®) necessary in neovascular age-related macular degeneration?
by: Nicola G Ghazi, et al.
Published: (2010) -
Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits
by: Sinapis C, et al.
Published: (2011) -
Bevacizumab (Avastin®) for the management of anterior chamber neovascularization and neovascular glaucoma
by: Dimitrios Brouzas, et al.
Published: (2009) -
Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
by: Juan Carlos Mesa Gutiérrez, et al.
Published: (2008) -
Massive choroidal hemorrhage after intravitreal administration of bevacizumab (Avastin®) for AMD followed by controlateral sympathetic ophthalmia
by: Dimitrios Brouzas, et al.
Published: (2009)